ONCR Oncorus

Oncorus to Participate in Upcoming Investor Conferences

Oncorus to Participate in Upcoming Investor Conferences

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences:

  • Evercore ISI 5th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.
  • Piper Sandler 34th Annual Healthcare Conference: Fireside chat on Thursday, December 1, 2022 at 12:30 p.m. ET in New York, NY.

A webcast of each event can be accessed by visiting the Investors & Media section of Oncorus’ website at . A replay of the webcast will be archived on Oncorus’ website for 90 days following the event.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to stimulate the immune system and transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) and self-amplifying viral RNA/LNP Platforms.

Designed as a next-generation viral immunotherapy, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity with immune stimulating payloads. Our lead HSV program, ONCR-177, currently in the clinic, is designed to be directly administered into a tumor, resulting in high local concentrations of therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering self-amplifying vRNA/LNP Platform, highlighted by our product candidates ONCR-021 and ONCR-788, involves a highly innovative, novel combination of RNA and LNP-based modalities designed to realize the potential of RNA medicines for cancer.

Please visit to learn more.



Investor Contact:

Stern Investor Relations

Julie Seidel

 



EN
23/11/2022

Underlying

ONCROncorus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncorus

 PRESS RELEASE
Free
ONCR ONCORUS

Oncorus Announces Workforce Reduction Plan

Oncorus Announces Workforce Reduction Plan ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus...

June 1, 2023 1 EN
 PRESS RELEASE
Free
ONCR ONCORUS

Oncorus Reports First Quarter 2023 Financial Results and Provides Busi...

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a fir...

May 22, 2023 1 EN
 PRESS RELEASE
Free
ONCR ONCORUS

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results an...

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administrationEnded the quarter with $62.2 million in cash, cash equivalents and investments to support next-generation RNA therapeutics pipeline ANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines co...

March 24, 2023 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
W WAYFAIR INC.
VEEV Veeva Systems I... ... (+48)

InsiderInsights Weekly Report: January 21, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

W WAYFAIR INC.
VEEV VEEVA SYSTEMS INC CLASS A
XOMA XOMA
SEAC SEACHANGE INTERNATIONAL INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MIXT MIX TELEMATICS ADR
MACK MERRIMACK PHARMACEUTICALS INC
HSKA HESKA CORPORATION
EOG EOG RESOURCES INC.
CMTL COMTECH TELECOMMUNICATIONS CORP.
CVV CVD EQUIPMENT
TZOO TRAVELZOO
CULP CULP INC.
MRAM EVERSPIN TECHNOLOGIES
JELD JELD-WEN HOLDING INC.
JNCE JOUNCE THERAPEUTICS
GTHX G1 THERAPEUTICS
APPN APPIAN
OPTN OPTINOSE
GIM TEMPLETON GLOBAL INCOME FUND
SRRK SCHOLAR ROCK HOLDING CORPORATION
LOVE LOVESAC
NGM NGM BIOPHARMACEUTICALS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ZYME ZYMEWORKS INC.
NREF NEXPOINT REAL ESTATE FINANCE
ZI INC.
RILY ZOOMINFO TECHNOLOGIES INC.
PCVX B. RILEY FINANCIAL
ONCR VAXCYTE
FET ONCORUS
PUBM FORUM ENERGY TECHNOLOGIES
RIDE PUBMATIC
LIXT LORDSTOWN MOTORS CORP (A)
COIN LIXTE BIOTECHNOLOGY HOLDINGS
HOWL COINBASE GLOBAL
XMTR INC.
MYO WEREWOLF THERAPEUTICS
HYZN INC.
XOS XOMETRY
JOBY INC.
APLD MYOMO
TEAM HYZON MOTORS INC.
PRTY XOS INC
JOBY AVIATION INC
APPLIED BLOCKCHAIN INC
ATLASSIAN CORPORATION
PARTY CITY HOLDCO
01/21/23 January 21, 2023 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
W WAYFAIR INC.
TSLA TESLA INC ... (+45)

InsiderInsights Weekly Report: January 7, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

W WAYFAIR INC.
TSLA TESLA INC
RNG RINGCENTRAL INC. CLASS A
MACK MERRIMACK PHARMACEUTICALS INC
CAMP CALAMP CORP.
TZOO TRAVELZOO
ICD INDEPENDENCE CONTRACT DRILLING
CULP CULP INC.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
MRAM EVERSPIN TECHNOLOGIES
JELD JELD-WEN HOLDING INC.
SVRA SAVARA
GTHX G1 THERAPEUTICS
LILA LIBERTY LATIN AMERICA A
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
LOVE LOVESAC
BYND BEYOND MEAT
FULC INC.
CMPR FULCRUM THERAPEUTICS
JYNT CIMPRESS PLC
HPK THE JOINT
PCVX HIGHPEAK ENERGY INC (A)
ONCR VAXCYTE
HQI ONCORUS
FET HIREQUEST INC.
PUBM FORUM ENERGY TECHNOLOGIES
ONDS PUBMATIC
LIXT ONDAS HOLDINGS
OLO LIXTE BIOTECHNOLOGY HOLDINGS
XMTR OLO
HYZN XOMETRY
AUGX INC.
LCID HYZON MOTORS INC.
JOBY AUGMEDIX
TBBK INC.
BLND LUCID GROUP INC
ROOT JOBY AVIATION INC
GLSI THE BANCORP
SNPX INC.
GCV ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
ROOT INC
GREENWICH LIFESCIENCES INC
SYNAPTOGENIX INC
THE GABELLI CONVERTIBLE AND INCOME SECURITIES FUND
INC.
01/08/23 January 8, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch